This is the authors' abstract. We don't add key points for this paper.
OBJECTIVE: To report the efficacy and safety of tocilizumab (TCZ) for giant cell arteritis (GCA). METHODS: A retrospective multicenter study that included 34 patients receiving TCZ for GCA. RESULTS: TCZ was effective in all but 6 patients, who still had mild symptoms. Mean glucocorticoid dose was tapered. One patient died and 3 patients had to stop TCZ therapy because of severe adverse events. Twenty-three patients stopped treatment; 8 of these experienced relapses after a mean of 3.5 ± 1.3 months. CONCLUSION: TCZ is effective in GCA. However, side effects occur. Whether this treatment has only a suspensive effect remains to be determined.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Régent et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: